<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="starglo-glofit-gemox-rrdlbcl-gregory">
    <meta name="study:title" content="PS1909 - Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of STARGLO">
    <meta name="study:fileName" content="Abstracts/STARGLO-GLOFIT-GEMOX-RRDLBCL-GREGORY-PS1909.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Glofitamab,Bispecific antibodies,Gemcitabine,Oxaliplatin,Chemotherapy,Rituximab,Monoclonal Antibody,Obinutuzumab,CIT,Glofit-GemOx,R-GemOx">

    <title>PS1909: STARGLO 2-Yr FU (Glofit-GemOx in R/R DLBCL) (Gregory) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> </head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PS1909 - STARGLO 2-Year Follow-Up: Glofitamab + GemOx vs R-GemOx in R/R DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996 2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=274)</h4>
                    <p>ASCT-ineligible R/R DLBCL Pts (≥1 prior LOT). Aim: Updated efficacy (OS, PFS, CR) & safety of Glofit-GemOx vs R-GemOx (STARGLO Ph III).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (Randomized 2:1)</h4>
                    <p>Glofit-GemOx (n=183; 8 cycles + 4 Glofit mono) vs R-GemOx (n=91; 8 cycles). Obi pre-tx for Glofit. Glofit step-up C1, then 30mg Q21D.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (Glofit-GemOx vs R-GemOx, 2-yr F/U)</h4>
                    <p>mOS: NE vs 13.5m (HR 0.60). mPFS: 13.8 vs 3.6m (HR 0.41). CR: 58.5% vs 25.3%. Pts in CR at EOT (Glofit-GemOx): 1yr PFS 82.4%.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Glofit-GemOx safety unchanged. CRS most common (Gr1 32%, Gr2 10.5%, Gr3 2.3%). Sustained OS/PFS benefit. Durable remissions.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PS1909 - Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of STARGLO</h1>
            <p class="abstract-sub-header">Gareth Gregory, Matthew Ku, Mark Hertzberg, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PS1909 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Glofitamab (CD20xCD3 bispecific Ab) showed durable responses as fixed-duration monotherapy in R/R DLBCL (≥2 prior LOT).</li>
                        <li>Phase III STARGLO trial: Glofitamab + GemOx (Glofit-GemOx) demonstrated OS and PFS benefit over Rituximab + GemOx (R-GemOx) in ASCT-ineligible R/R DLBCL.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To present updated efficacy (OS, PFS, CR rate) and safety of Glofit-GemOx vs R-GemOx in R/R DLBCL patients (pts) after ≥1 LOT from the Phase III STARGLO trial (NCT04408638), including landmark analyses of pts in CR.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Trial: STARGLO (Phase III, randomized, NCT04408638).</li>
                        <li>Patients (N=274): ASCT-ineligible R/R DLBCL, ≥1 prior LOT. Randomized 2:1.
                            <ul class="list-circle list-inside ml-4">
                                <li>Glofit-GemOx arm (n=183): 8 cycles GemOx + Glofitamab, then 4 cycles Glofitamab monotherapy.</li>
                                <li>R-GemOx arm (n=91): 8 cycles R-GemOx.</li>
                            </ul>
                        </li>
                        <li>Stratification: Number of prior LOT (1 vs ≥2), refractoriness to last therapy.</li>
                        <li>Glofitamab Dosing: Obinutuzumab pretreatment. C1: weekly step-up (2.5mg, 10mg). From C2 D1: 30mg target dose Q21D.</li>
                        <li>Eligibility Note: Pts with only 1 prior LOT must have been ASCT-ineligible.</li>
                        <li>Primary Endpoint: OS. Secondary: IRC-assessed PFS, CR rate. Landmark analysis of pts in CR at End of Treatment (EOT).</li>
                        <li>Data Cutoff: June 17, 2024 (Median follow-up: 24.7 months).</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">STARGLO Phase III Trial Design</h3>
                        <div class="schema-enrollment">
                            <strong>R/R DLBCL Pts, ASCT-ineligible, ≥1 Prior LOT (N=274)</strong>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group justify-around">
                            <div class="schema-phase cohort-a" style="flex-basis: 65%;">
                                <strong>Glofitamab + GemOx (n=183)</strong>
                                <span>Obi Pre-tx</span>
                                <span>Glofit (step-up C1: 2.5/10mg; C2+ 30mg Q21D)</span>
                                <span>+ GemOx (8 cycles)</span>
                                <span>Then Glofitamab mono (4 cycles)</span>
                            </div>
                             <div class="schema-phase cohort-b" style="flex-basis: 33%;">
                                <strong>Rituximab + GemOx (n=91)</strong>
                                <span>R-GemOx (8 cycles)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Primary EP: Overall Survival (OS)</span>
                           <span>Secondary EPs: PFS (IRC), CR Rate</span>
                           <span>Landmark Analysis: OS/PFS in CR pts at EOT</span>
                           <span>Safety</span>
                        </div>
                    </div>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=274)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Baseline characteristics unchanged from primary analysis and well-balanced.</li>
                        <li>1 Prior LOT: 62.8% (172 pts).</li>
                        <li>≥2 Prior LOT: 37.2% (102 pts).</li>
                        <li>Primary Refractory: 55.8% (153 pts).</li>
                        <li>Refractory to Last Therapy: 60.6% (166 pts).</li>
                    </ul>
                </div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (2-Year Follow-Up)</h2>
                    <p class="text-sm font-semibold mt-1 mb-1">Glofit-GemOx vs R-GemOx:</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>Median OS:</strong> Not Evaluable (NE) vs 13.5 months (HR 0.60, 95% CI: 0.42–0.85).</li>
                        <li><strong>Median IRC-PFS:</strong> 13.8 months vs 3.6 months (HR 0.41, 95% CI: 0.29–0.58).</li>
                        <li><strong>CR Rate:</strong> 58.5% vs 25.3%.</li>
                    </ul>
                     <div class="chart-container my-4">
                        <svg id="stargloSurvivalChart" width="400" height="300"></svg>
                        <div id="stargloSurvivalLegend" class="legend"></div>
                    </div>
                    <p class="text-sm font-semibold mt-3 mb-1">Glofit-GemOx Treated Patients in CR (n=107):</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Median Duration of CR (mDoCR): Not Reached (95% CI: 27.2–NE).</li>
                        <li>Median CR Follow-up: 18.2 months (range: 15.2–19.3).</li>
                    </ul>
                    <p class="text-sm font-semibold mt-3 mb-1">Patients in CR at EOT with Glofit-GemOx (n=82):</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>OS Rate at 1 year post-EOT: 89.3%.</li>
                        <li>PFS Rate at 1 year post-EOT: 82.4%.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary (Glofit-GemOx Arm)</h2>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Safety profile unchanged from primary analysis.</li>
                        <li><strong>Cytokine Release Syndrome (CRS) - Most Common AE:</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>Grade 1: 32.0%</li>
                                <li>Grade 2: 10.5%</li>
                                <li>Grade 3: 2.3%</li>
                            </ul>
                        </li>
                        <li>Events consistent with ICANS: 4 patients (all concurrent with CRS; most Gr 1–2 [n=3]).</li>
                        <li>Exploratory biomarker and immune recovery data will be presented.</li>
                    </ul>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>With 2 years of follow-up, Glofit-GemOx continued to demonstrate a clinically meaningful and superior benefit in OS and PFS compared to R-GemOx in ASCT-ineligible patients with R/R DLBCL.</li>
                <li>High CR rates were achieved with Glofit-GemOx, and most patients (82%) in CR at EOT remained in remission at 1 year post-EOT.</li>
                <li>The safety profile of Glofit-GemOx was consistent with the known risks of each drug, with CRS being the most common AE.</li>
                <li>Updated analyses confirm durable remissions and maintained OS benefit with fixed-duration Glofit-GemOx in this patient population.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>Ab, Antibody; AE, Adverse Event; ASCT, Autologous Stem Cell Transplant; C, Cycle; CI, Confidence Interval; CIT, Chemoimmunotherapy; CR, Complete Remission; CRS, Cytokine Release Syndrome; D, Day; DLBCL, Diffuse Large B-Cell Lymphoma; DoCR, Duration of Complete Response; EOT, End of Treatment; EP, Endpoint; F/U, Follow-up; GemOx, Gemcitabine and Oxaliplatin; Glofit, Glofitamab; Gr, Grade; HR, Hazard Ratio; ICANS, Immune Effector Cell-Associated Neurotoxicity Syndrome; IRC, Independent Review Committee; LOT, Lines of Therapy; m, Median; NE, Not Evaluable; NHL, Non-Hodgkin Lymphoma; Obi, Obinutuzumab; OS, Overall Survival; PFS, Progression-Free Survival; Ph, Phase; Pts, Patients; Q21D, Every 21 Days; R, Rituximab; R/R, Relapsed or Refractory; Tx, Treatment; vs, Versus.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Gregory G, Ku M, Hertzberg M, et al. Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of STARGLO. Abstract #PS1909 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PS1909 | Abstract Release: 05/22/25 | Presentation: 06/14/2025</p>
            <p class="text-xs italic mt-1">© 2025 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2025 ASCO Annual Meeting. All rights reserved.</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div> <script defer src="abstract_features.js"></script>
    <script>
        function drawStargloSurvivalChart(containerId, legendContainerId) {
            const chartTitle = "STARGLO: Glofit-GemOx vs R-GemOx (2-Year F/U)";
            // Data: mOS: NE vs 13.5m; mPFS: 13.8m vs 3.6m
            // For NE, we use a placeholder value for visualization that is higher than other values.
            const NE_Placeholder_Months = 30; // Arbitrary high value for "Not Evaluable" visualization
            
            const chartData = [
                { group: "Glofit-GemOx", mOS: NE_Placeholder_Months, mPFS: 13.8, CR_Rate: 58.5 },
                { group: "R-GemOx", mOS: 13.5, mPFS: 3.6, CR_Rate: 25.3 }
            ];
            const subgroups = ["mOS", "mPFS", "CR_Rate"];
            const displayLabels = {
                "mOS": "Median OS (months)",
                "mPFS": "Median PFS (months)",
                "CR_Rate": "CR Rate (%)"
            };
            const units = {
                "mOS": "m",
                "mPFS": "m",
                "CR_Rate": "%"
            };
            const yMaxValues = { // Define different y-axis scales for different metrics
                "mOS_mPFS": NE_Placeholder_Months + 5,
                "CR_Rate": 100
            };


            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);
            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 400;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.95, 300);
            }
            
            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");
            const margin = { top: 60, right: 20, bottom: 70, left: 60 };
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <=0) return;

            const g = svg.append("g").attr("transform", `translate(${margin.left},${margin.top})`);
            const groups = chartData.map(d => d.group);
            
            const xScaleGroups = d3.scaleBand().domain(groups).range([0, chartWidth]).padding(0.4);
            const xScaleSubgroups = d3.scaleBand().domain(subgroups).range([0, xScaleGroups.bandwidth()]).padding(0.05);
            
            // Using a single Y scale for simplicity, max of all values.
            // More complex would be dual y-axes or separate charts.
            // For this, we'll scale to the max of OS/PFS, and CR Rate will be on the same 0-100 scale.
            const maxYScale = Math.max(yMaxValues.mOS_mPFS, yMaxValues.CR_Rate);
            const yScale = d3.scaleLinear().domain([0, maxYScale]).range([chartHeight, 0]);

            const color = d3.scaleOrdinal()
                .domain(subgroups)
                .range(["var(--sobi-teal)", "var(--sobi-orange)", "var(--sobi-light-blue)"]);

            g.append("g").attr("transform", `translate(0,${chartHeight})`).call(d3.axisBottom(xScaleGroups))
                .selectAll("text").attr("class", "axis-text").style("font-size", "10px").attr("transform", "rotate(-10) translate(-5,0)").style("text-anchor", "end");
            
            g.append("g").call(d3.axisLeft(yScale).ticks(6).tickFormat(d => (d === NE_Placeholder_Months && chartData.some(cd => cd.mOS === NE_Placeholder_Months)) ? "NE" : d.toFixed(0)))
                .selectAll("text").attr("class", "axis-text").style("font-size", "10px");
            
            g.append("text").attr("transform", "rotate(-90)").attr("y", 0 - margin.left + 15).attr("x", 0 - (chartHeight / 2))
                .attr("dy", "1em").style("text-anchor", "middle").attr("class", "axis-label").text("Value (Months or %)");

            g.append("g").attr("class", "grid").call(d3.axisLeft(yScale).ticks(6).tickSize(-chartWidth).tickFormat(""))
                .selectAll("line").style("stroke", "var(--sobi-light-gray)").style("stroke-opacity", "0.7");

            const groupBars = g.selectAll(".group-bar").data(chartData).enter().append("g")
                .attr("class", "group-bar").attr("transform", d => `translate(${xScaleGroups(d.group)},0)`);

            groupBars.selectAll("rect")
                .data(d => subgroups.map(key => ({ key: key, value: d[key] })))
                .enter().append("rect")
                .attr("x", d => xScaleSubgroups(d.key)).attr("y", d => yScale(d.value))
                .attr("width", xScaleSubgroups.bandwidth()).attr("height", d => chartHeight - yScale(d.value))
                .attr("fill", d => color(d.key)).attr("rx", 2).attr("ry", 2);

            groupBars.selectAll(".bar-label")
                .data(d => subgroups.map(key => ({ key: key, value: d[key] })))
                .enter().append("text")
                .attr("class", "chart-label")
                .attr("x", d => xScaleSubgroups(d.key) + xScaleSubgroups.bandwidth() / 2)
                .attr("y", d => yScale(d.value) - 4).attr("text-anchor", "middle")
                .style("font-size", "9px").style("fill", "var(--sobi-dark-text)")
                .text(d => d.value === NE_Placeholder_Months ? "NE" : `${d.value.toFixed(1)}${units[d.key]}`);
            
            svg.append("text").attr("x", svgWidth / 2).attr("y", margin.top / 2)
                .attr("text-anchor", "middle").style("font-size", "13px").style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)").text(chartTitle);

            const legendData = subgroups.map(key => ({ label: displayLabels[key], color: color(key) }));
            const legendItems = legendContainer.selectAll(".legend-item").data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }
        
        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => { clearTimeout(timeout); func(...args); };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawStargloChart = debounce(() => drawStargloSurvivalChart("#stargloSurvivalChart", "#stargloSurvivalLegend"), 250);
        
        window.addEventListener('resize', debouncedDrawStargloChart);
        document.addEventListener('DOMContentLoaded', debouncedDrawStargloChart);
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawStargloChart, 0); 
        }
    </script>
</body>
</html>
